
The Manager, Document Control will support the head of Quality Systems to define and implement the corporate requirements for the regulated Document Control Program. This role serves as a critical member of the Quality Assurance team, responsible for the administration, maintenance, and continuous improvement of the Document and Records management process within the electronic Quality Management System (eQMS). This role ensures that all controlled documents and electronic records comply with applicable regulations and internal standards, including, but not limited to 21 CFR Parts 11, and Parts 210/211. The Document Controller serves as both a subject matter expert and a hands-on practitioner, owning end-to-end document lifecycle management activities while also training and mentoring colleagues on system use and internal requirements.
Responsibilities
Qualifications
Knowledge and Skills
E/E/O
Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
E-Verify
Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish)

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.